Cash on Hand for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported cash and short-term investments is $2.91B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingCash on HandSwitch metric
Latest period
$2.91B
YoY change
+7.9%
5Y CAGR
+9.2%
Peak year (2025)
$2.91B
Latest annual
$2.91B
Cash on Hand history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Cash on Hand history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $2.91B | +7.9% | ||
| 2024 | $2.69B | +10.5% | ||
| 2023 | $2.44B | +11.3% | ||
| 2022 | $2.19B | -10.0% | ||
| 2021 | $2.44B | +29.9% | ||
| 2020 | $1.87B | +22.0% | ||
| 2019 | $1.54B | +41.7% | ||
| 2018 | $1.08B | -35.9% | ||
| 2017 | $1.69B | +169.7% | ||
| 2016 | $626.80M | -42.0% | ||
| 2015 | $1.08B | +55.1% | ||
| 2014 | $696.69M | +183.4% | ||
| 2013 | $245.87M | +100.2% | ||
| 2012 | $122.81M | -16.1% | ||
| 2011 | $146.40M | -37.2% | ||
| 2010 | $233.13M | -17.2% | ||
| 2009 | $281.40M | -34.6% | ||
| 2008 | $430.39M | +10.4% | ||
| 2007 | $389.95M | +79.5% | ||
| 2006 | $217.26M | +171.6% | ||
| 2005 | $80.00M | +73.7% | ||
| 2004 | $46.05M | +98.5% | ||
| 2003 | $23.19M | +49.9% | ||
| 2002 | $15.48M | — |
Cash on Hand values are taken from Alnylam Pharmaceuticals's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Alnylam Pharmaceuticals (ALNY) most recent annual cash and short-term investments stands at $2.91B (2025) – grew 7.9% year-over-year.
Alnylam Pharmaceuticals cash and short-term investments compound annual growth for the 2020–2025 (5 years) window is +9.2%, sustaining 3 straight years of year-over-year growth.
2025 marks the peak cash and short-term investments at $2.91B, with the historical low of $15.48M recorded in 2002.
Alnylam Pharmaceuticals (ALNY) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $11.85B.
Alnylam Pharmaceuticals Cash on Hand by Year
Alnylam Pharmaceuticals Cash on Hand 2025: $2.91B
Alnylam Pharmaceuticals cash and short-term investments in 2025 was $2.91B, grew 7.9% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Cash on Hand 2024: $2.69B
Alnylam Pharmaceuticals cash and short-term investments in 2024 was $2.69B, grew 10.5% from 2023.
Alnylam Pharmaceuticals Cash on Hand 2023: $2.44B
Alnylam Pharmaceuticals cash and short-term investments in 2023 was $2.44B, grew 11.3% from 2022.
Alnylam Pharmaceuticals Cash on Hand 2022: $2.19B
Alnylam Pharmaceuticals cash and short-term investments in 2022 was $2.19B, declined 10.0% below 2021.
Alnylam Pharmaceuticals Cash on Hand 2021: $2.44B
Alnylam Pharmaceuticals cash and short-term investments in 2021 was $2.44B.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Cash on Hand
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's cash and short-term investments?
- Latest reported cash and short-term investments for Alnylam Pharmaceuticals (ALNY) is $2.91B (period ending December 31, 2025).
How has Alnylam Pharmaceuticals cash and short-term investments changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) cash and short-term investments changed +7.9% year-over-year on the latest annual filing.
What is the long-term growth rate of Alnylam Pharmaceuticals cash and short-term investments?
- Alnylam Pharmaceuticals (ALNY) cash and short-term investments compound annual growth rate is +9.2% over the most recent 5 years available.
When did Alnylam Pharmaceuticals cash and short-term investments hit its highest annual value?
- Alnylam Pharmaceuticals cash and short-term investments reached its highest annual value of $2.91B in 2025.
What was Alnylam Pharmaceuticals cash and short-term investments in 2024?
- Alnylam Pharmaceuticals (ALNY) cash and short-term investments in 2024 was $2.69B.
What was Alnylam Pharmaceuticals cash and short-term investments in 2025?
- Alnylam Pharmaceuticals (ALNY) cash and short-term investments in 2025 was $2.91B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.